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Abstract: There is growing con-
cern that poor experimental design
and lack of transparent reporting
contribute to the frequent failure of
pre-clinical animal studies to trans-
late into treatments for human
disease. In 2010, the Animal Re-
search: Reporting of In Vivo Exper-
iments (ARRIVE) guidelines were
introduced to help improve report-
ing standards. They were published
in PLOS Biology and endorsed by
funding agencies and publishers
and their journals, including PLOS,
Nature research journals, and other
top-tier journals. Yet our analysis of
papers published in PLOS and
Nature journals indicates that there
has been very little improvement in
reporting standards since then. This
suggests that authors, referees, and
editors generally are ignoring
guidelines, and the editorial en-
dorsement is yet to be effectively
implemented.
Introduction
Pre-clinical animal models of human
neurological disease have delivered rela-
tively few treatments [1,2]. Despite reports
of over 1,000 treatments effective in
animal models of multiple sclerosis (MS),
very few treatments have so far made it to
the marketplace following initial develop-
ment in disease-related animal models [2].
Similarly, in the case of stroke treatments,
essentially no pre-clinical research has
translated for human benefit [1]. What’s
worse, some treatments that ameliorate
autoimmunity in animals, such as gamma
interferon and tumour necrosis factor–
specific antibodies, may exacerbate disease
in humans [3–6]. The reasons why drugs
that look promising in animal studies fail
to translate into drug treatments for
human disease include the following:
issues with animals studies, such as the
use of excessive doses and a timing of drug
delivery that does not reflect that applied
in established human disease [2,7]; issues
with clinical studies, such as the use of
immunosuppressive drugs in progressive
MS at a stage that is no longer responsive
to peripheral immunosuppression [8]; and
issues related to commercial interests, such
as a lack of patent protection that provides
no incentive for clinical development.
One important issue with animal studies
is the widespread lack of transparent,
quality reporting of study design and
implementation [1,2,9]. Recent analyses
have found, for example, that 86%–87%
of papers reporting animal studies did not
describe randomisation and blinding
methods, and more than 95% of them
did not report on the statistical power of
the studies to detect a difference between
experimental groups [2,9]. This under-
mines the credibility of pre-clinical animal
research. Inadequate reporting of key
aspects of experimental design may reduce
the impact of studies and could act as a
barrier to translation by preventing repe-
tition or inclusion in meta-analysis.
In June 2010, PLOS Biology published
guidelines for reporting of experiments
with animals [10]. The Animal Research:
Reporting of In Vivo Experiments (ARRI-
VE) guidelines were drawn up by a group
of statisticians, funders, and editors on the
initiative of the UK National Centre for
the Replacement, Refinement and Reduc-
tion of Animals in Research to improve
consistency in reporting, notably, of pre-
clinical animal studies. The ARRIVE
guidelines consist of a 20-item checklist
and recommendations for authors on
reporting study design, experimental pro-
cedures, and experimental animals [10].
The ARRIVE guidelines are similar to the
CONSORT (Consolidated Standards of
Reporting Trials) statement required for
reporting human clinical trials, which
were introduced to alleviate inadequate
reporting. Over 300 research journals
(including those published by the Nature
Publishing Group, PLOS, and BioMed
Central) have endorsed the ARRIVE
guidelines. So too have the major UK
funding agencies (including the Wellcome
Trust, the Biotechnology and Biological
Sciences Research Council, and the Med-
ical Research Council) and learned socie-
ties; the ARRIVE guidelines also form
part of the US National Research Council
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guidance for the description of animal
research in scientific publications [11].
Despite these good intentions, however,
the ARRIVE guidelines are not being
implemented by authors, reviewers, and
journal editors [12–14]. Following an
initial study to monitor the implementa-
tion and reporting of one specific statistical
analysis in experimental design (see Text
S1), we investigated the general adequacy
of reporting on animal models of MS, a
neuroimmunological disorder. Our survey
of the literature uncovers worrying inad-
equacies in the reporting of experimental
design, selecting appropriate statistical
analyses, and applying key points in the
ARRIVE guidelines.
Lies, Damn Lies, and Statistics
Experimental autoimmune encephalo-
myelitis (EAE) in rodents is the principal
model used to study the neurological and
autoimmune mechanisms of MS in par-
ticular and autoimmunity in general.
Rodents with EAE respond rapidly to
drugs, and obvious clinical signs, such as
limb paralysis, can be used to deduce
underlying inflammatory aspects of the
disease [7], so researchers can avoid the
extensive tissue sampling and pathology
tests required in other animal models. This
ease of monitoring clinical disease and the
responsiveness of the affected animals to
drugs make the EAE model very amenable
to drug testing. The clinical signs in
animals are recorded using a subjective,
non-linear motor-disability scale similar to
the Kurtzke Expanded Disability Status
Scale (EDSS) used to monitor MS in
humans [15]. The severity of symptoms is
scored numerically—usually as tail and
limb paresis (i.e., partial paralysis), and
sometimes as erection of the hair [2]—and
the numerical score can then be used in
statistical analysis. The degree of inflam-
mation and the clinical scores reflecting
ascending paresis of the limbs [15,16] are
clearly related; however, their relationship
is non-linear.
Most researchers, in our opinion, make
a fundamental error when reporting their
scoring results: they use descriptive statis-
tics, such as means and standard devia-
tions, that assume the data are continuous,
normally distributed, and of equal vari-
ance, and then apply parametric statistical
tests that assume a specific population
distribution for the data (such as ANOVA,
t-tests, or regression analysis) to test the
significance of their findings [13,17].
Medians and ranges, which are perhaps
more statistically appropriate, may not
have the visual impact of a simple factor
measuring differences between two treat-
ment groups, and they lack the descriptive
power of means and deviations [7].
Nevertheless, monitoring of treatment
effects should be analysed using non-
parametric statistical tests that make no
assumptions about population distribu-
tions (such as the Mann–Whitney U test
or Kruskall–Wallace test) to compare
treatment groups when the data derive
from arbitrary scale measurements, such
as the motor-disability scale used in the
EAE model; assuming a specific popula-
tion, as is done for parametric statistics, is
not appropriate [13,17]. Although statisti-
cal arguments may be made for the use of
parametric statistics on non-parametric
data [6,17], in the EAE literature a large
variety of statistical approaches are cur-
rently being applied to test essentially the
same hypothesis of a difference in outcome
for a drug or gene manipulation treatment
measured with the same non-linear, sub-
jective assays.
Are You Applying the Wrong
Statistics?
We analysed 180 primary papers ar-
chived in PubMed over a six-month
period that compared EAE scores in two
or more groups of animals (part 1 in Text
S1; Table S1) to assess whether parametric
tests or non-parametric tests were applied
to experiments that tested the same
hypothesis with very similar datasets
[17]. We adopted the debatable position
that non-parametric statistics should be
applied to clinical disease. Thirteen per-
cent (95% confidence interval [CI] 8.7%–
18.5%) of articles did not report statistical
analyses at all, and only 39% (95% CI
32.5%–46.8%) correctly used non-para-
metric statistical tests on non-parametric
neurological scoring data. As many as
55% (95% CI 46.7%–62.3%) of studies,
however, included analyses based on what
we consider to be inappropriate statistical
tests, and we saw no consistency in
statistical tests of essentially the same
hypothesis (part 2 in Text S1). The
inappropriate use of statistics was inde-
pendent of the impact factor of the journal
in which the paper was published
(Figure 1). This shows that reporting of
inappropriate statistics occurs throughout
the range of high- and low-impact-factor
publications. Indeed, in journals that had
an impact factor greater than ten, almost
twice as many papers used incorrect
statistics or failed to report statistics (10/
107; 95% CI 5.2%–16.4%) as reported
statistics correctly (3/69; 95% CI 1.5%–
12.0%).
This observation led us to study papers
on EAE published in several Nature
journals, Science, Cell, and other top-
ranking journals over two years (part 3
in Text S1; Table S2). Only 4% of EAE
papers in these top-ranking journals (1/
26; 95% CI 0.7%–18.9%) reported ade-
quate use of a single non-parametric
analysis of data on neurological scores,
and 67% (95% CI 41.7%–84.8%) used
only a t-test, which is not statistically
justified [17]. Possibly some studies re-
porting inappropriate statistical methods
were corrected during the peer-review
process; however, this survey demon-
strates significant weakness in the peer-
review process and inconsistencies in
reporting and statistical accuracy even
between articles in the same journal. Most
studies on EAE published during this
period appeared in the Journal of Immunol-
ogy (n = 23) and the Journal of Neuroimmu-
nology (n = 13), in which adequate non-
parametric statistics were reported in 39%
and 31% of cases, respectively.
Non-parametric statistics will tend to
approximate to parametric statistics when
large group sizes are used; however,
studies of EAE and most other animal
models [2,9] typically have small sample
sizes, a limited scale size, and lack of
appropriate ‘‘power/sample size calcula-
tions’’ (which ensure that there is a
sufficient sample size in the experimental
design to detect an effect of treatment, if
there is one). In such cases, the chances of
type I errors (i.e., false positives) against a
null hypothesis of no treatment effect are
enhanced, and type I errors probably
occur. Consequently, these studies overes-
timate the benefit of the treatment.
Consultation with an expert statistician to
select an appropriate and valid test will
minimise the chances not only of type I
errors but also of type II errors (i.e., false
negatives), which would fail to identify
effective treatments.
Ensuring the use of appropriate statisti-
cal analysis is a common problem in many
fields of biology [17–20]. Our survey
suggests that the ‘‘high quality’’ journals
are setting a poor standard for others to
follow [19,21]. While focussing on techni-
cally challenging and innovative science,
many journals fail to ensure that the basic
standards of experimental design and data
analysis are adhered to. One solution to
this problem is to have additional statisti-
cal review of submitted manuscripts (as is
often done by journals in the health
sciences); also, learned societies might
suggest methods of analysis of standard
outcomes and data reporting to their
members [7,12,13].
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Are the Guidelines Being
Ignored?
The ARRIVE guidelines lay out stan-
dards for reporting in all sections of
published articles: the introduction (the
background and objectives of the study),
the methods (an ethical statement, de-
scription of the study design, experimental
procedures and animals, housing and
husbandry, sample size, and statistical
methods), the results (numbers analysed
and adverse events), the discussion (inter-
pretation of the data, their implications,
and potential for translation), and the
acknowledgments. Given our findings of
poor experimental design related to the
use of appropriate statistics as outlined in
the ARRIVE guidelines, we investigated
whether other key aspects of the guidelines
were being implemented.
We conducted another literature search
for papers published during the two years
before and two years after endorsement of
the ARRIVE guidelines by all Nature and
PLOS journals (Text S1; Figure 2). Many
papers reported studies of EAE both
before (n = 15, PLOS journals; n = 15,
Nature journals) and after (n = 30, PLOS
journals, nearly all in PLOS ONE; n = 14,
Nature journals) publication of the ARRI-
VE guidelines (Table S3). We evaluated
the articles in four key areas: ethics
(whether there was ethical oversight and
approval for the study via an institutional
review), study design (allocation to
groups/randomisation and blinding), ex-
perimental animals (species, sex, age, and
group size), and sample size estimation/
power calculations. We did not assess all
20 recommendations of the guidelines,
because previous studies have suggested
that very few papers fully incorporate
them all [14].
Journals now commonly request ethical
review statements, which featured in most
papers in PLOS journals (93% pre-AR-
RIVE and 94% post-ARRIVE), Nature
journals (100% pre-ARRIVE and 100%
post-ARRIVE), and other journals [2].
Methods to reduce bias and the chance of
false-positive reporting, by contrast, were
rarely reported, although this does not
mean they were not part of the experi-
mental design [1,2,10]. We found that the
percentage of studies, in the two years
after endorsement of the ARRIVE guide-
lines, reporting blinding in their experi-
mental design was similar to that in past
surveys (20% in PLOS journals and 21%
in Nature journals); however, fewer than
10% of the relevant studies in either
Nature or PLOS journals reported rando-
misation (10% in PLOS journals and 0%
in Nature journals), and even fewer
mentioned any power/sample size analysis
(0% in PLOS journals and 7% in Nature
journals). Animal characteristics (species,
sex, and age) and the number of animals
used in a study can potentially influence
experimental outcomes. We found an
increase in the incidence of reporting of
species (100% in both PLOS and Nature
journals), sex (68% in PLOS journals and
79% in Nature journals), and age of
animals (87% in PLOS journals and
79% in Nature journals) following publi-
cation of the ARRIVE guidelines. Not all
papers reported this simple information,
however (Figure 2). Reporting of statistical
analysis was common, but, as mentioned
above, use of parametric statistics on non-
parametric data was the norm in EAE
experiments both before and after en-
dorsement of the ARRIVE guidelines; in
fact, application of non-parametric statis-
tics to neurological score data occurred
less often in Nature journals after publica-
tion of the guidelines than before (25%
pre-ARRIVE versus 7% post-ARRIVE).
Some of the studies examined here may
have been designed before the introduc-
tion of the ARRIVE guidelines, but this
should not have precluded appropriate
reporting had the journals adopted the
standards set out in the guidelines and
provided the space to document this
information. The possibility of publishing
supplementary information online makes
any argument about space limitation
unfounded. Our findings suggest that,
despite their endorsement by these jour-
nals, the guidelines have had little impact
on reporting standards in published pa-
pers, at least in the neuroimmunological
field, but the problem is likely to be more
widespread [1,2,7,16]. Evidence suggests
that problems of analysis, design, and
reporting apply to pre-clinical animal
modelling throughout neuroscience and
more generally in all areas of biological
research [1,2,10,14,22]. Indeed, our find-
ings on randomisation and blinding
(Figure 2) are similar to those of a previous
survey analysing 500 papers for general-
ised biology [10].
How Might Journals Improve
Reporting?
Fully implementing every aspect of the
ARRIVE guidelines is clearly outside the
current reporting norms in biology [7,14]
and seems unlikely to occur without a
major change in the publication process.
Endorsements of the ARRIVE guidelines
are meaningless unless the signatories
actually intend to implement them. The
standard practice now to include report-
ing of ethical approval obtained before
Figure 1. Inappropriate use of parametric statistics applied to non-parametric data in
comparisons of treatments for EAE. Papers reporting differences between groups of animals
with EAE were assessed to determine whether the studies reported the statistical analysis
method, and whether they used non-parametric or parametric statistics to analyse non-
parametric neurological scoring data (n= 152). Each publication was attributed an impact score
according to the 2011 Web of Science impact factor for each journal. Some journals did not yet
have an impact factor; papers in these journals were assigned an impact score of zero. The
horizontal line shows the median impact score.
doi:10.1371/journal.pbio.1001756.g001
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publication is one example where editorial
action and a change in reporting behav-
iour has made a positive change: the
majority of studies report on this now,
compared to low levels of reporting a few
years ago [2]. This demonstrates that it is
feasible to implement certain reporting
standards.
In response to claims that several
publications in Nature journals contained
irreproducible findings, the publisher in-
troduced an editorial measure on 1 May
2013 to ensure that all papers published in
Nature journals include key methodolog-
ical details [23]. Authors must now submit
a reporting checklist alongside manu-
scripts. In addition, Nature journals have
removed space restrictions on the methods
sections of their papers to allow authors to
describe studies comprehensively. Some
journals we looked at (12/169 in January
2013) and all PLOS journals except PLOS
ONE (in December 2012) had yet to
incorporate any requirements to use the
ARRIVE guidelines when reporting into
their instructions to authors. It seems
essential for all journals not only to state
their position on the ARRIVE guidelines,
but also to give clear guidance to authors
on how they should be applied and then to
implement a policy of monitoring to
document compliance [24,25].
Some aspects of the ARRIVE guide-
lines, such as justification of selection of
species and strain of animal used and the
route and timing of delivery of agents [10],
often form part of the ethical review
process, which is currently being reported
[2,10], so there is no need to repeat this
information in a paper. Similarly, it would
be tedious to read the same justification for
why mice were used in each paper in a
journal that publishes mainly work onmice.
Clinical studies are more diverse than
mouse studies in their selection of patients,
still in many pre-clinical studies the same
methodology is used time and time again. A
pragmatic approach might be to implement
the most important aspects of the guidelines
[3,4], such as reporting the extent of
blinding and randomisation [2,10,11].
Likewise, in clinical trials sample size/
power calculations are important to limit
false-negative findings, whereas this is
rarely reported in animal studies that are
invariably positive [1,2,26].
For journals such as PLOS Medicine and
PLOS Biology that publish very few articles
describing comparisons of treatment ef-
fects in vivo in animals, it would be
relatively easy for editors to scrutinise the
reporting in these papers. PLOS ONE
currently publishes over 20,000 articles a
year, however, so the scrutinising task
must fall to the referees, who are clearly
paying little attention at the moment to
this aspect of the peer-review process.
Factors they might consider that may
impact the suitability of a study for
publication include side effects of drugs,
which may be apparent if specifically
looked for [27,28], the presence of infec-
tions in animals bought from commercial
breeders, common defects in vision, hear-
ing, etc., in lab mouse strains such as
C57BL/6, BALB/c, and CBA/J [29,30],
and small sample size [1,2,10]. Lack of
reporting may be because there is a
publication bias toward reporting positive
results [31,32]. The review process might
be better employed to assess the statistics
being applied in an attempt to limit the
publication of false-positive results. This
approach could improve the potential for
translation, as it would reduce the number
of ineffective drugs being tested in the
clinic for humans [2].
There may be a regional influence in
the adoption of the ARRIVE guidelines,
which were generated in the United
Kingdom and were initially adopted by
UK-based organisations. None of the
senior authors of papers in our analysis
were from UK-based laboratories, perhaps
explaining their unfamiliarity with the
guidelines. The guidelines have now
been published in international journals
and form part of recommendations
made by the US National Research
Council Institute for Laboratory Animal
Research [11,12], however, and ultimately,
Figure 2. Impact of endorsement of ARRIVE guidelines on reporting of EAE studies in
PLOS and Nature journals. Papers reporting differences between groups of animals with EAE
were assessed over the two years before and the two years after the endorsement of the ARRIVE
guidelines. The data show reporting of various aspects of experimental design in (A) PLOS (n= 46)
and (B) Nature journals (n= 30).
doi:10.1371/journal.pbio.1001756.g002
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it remains the responsibility of the
journal to enforce their application.
Can ARRIVE Be Even More
Human?
Recently, Gillman and colleagues sug-
gested in PLOS Biology that the ARRIVE
guidelines should be even more like
guidelines for human randomised con-
trolled trials, which require public regis-
tration of studies before they are per-
formed [33]. This may be impractical,
however, because animal studies often
involve not a single experiment, as in a
clinical trial, but a series of experiments
that may evolve sometimes over a number
of years. Public registration of experiments
would also require a change in the
patenting process, which often requires
non-disclosure of the invention for patent
validity. In addition, the results from
animal experiments are crucial when filing
patents. Changes to the requirements for
reporting of animal experiments within
patents might achieve the desired effect of
giving translational animal studies trans-
parency if they are to be used to support
drug development for humans. The patent
process does not currently have the
perceived rigor of the peer-review process,
as patents are judged from a legal
perspective, but a consistent reporting
standard could easily be adopted. This
would require government support, but it
would be in the public interest to uphold
high-quality reporting standards. As uni-
versities want to exploit the inventions of
their scientists, there would also be an
incentive to adopt common reporting
standards for the publishing and patenting
worlds. As an initial step, the priority is
that researchers adopt core elements of
quality experimental design and reporting
[12,13].
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